Company / Accounts Receivable
Cytokinetics Accounts Receivable History
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Accounts Receivable
$17.8M
FY2025
5-year range
$147.0K / $51.8M
FY2021-FY2025
Trend
+6.7%
vs FY2024
Sector context
#90 of 113
Health Care
What the data says
Cytokinetics's accounts receivable of $18M is lower than 80% of companies in the Health Care sector (FY2025). Accounts Receivable has increased for 3 consecutive years, from $147,000 in FY2022 to $18M in FY2025.
Based on SEC 10-K filings.
$18M in FY2025 with a 5-year CAGR of +32.1%.
Improved from $1M to $18M over the past 2 years.
Health Care sector context is included.
Accounts Receivable over time
Growth rates
- 3-Year CAGR
- +394.4%
- 5-Year CAGR
- +32.1%
- 10-Year CAGR
- -
Sector benchmark
Bottom 20% in Health CareTop 80% of 113This company $17.8M Sector average $1.1B
▼
-98.4% below sector average
Key checks
Key Insights
- Cytokinetics's accounts receivable has grown for 3 consecutive years.
- 5-year CAGR of +32.1%, indicating consistent growth.
- In FY2025, accounts receivable increased 6.7% year-over-year.
- Ranks #90 out of 113 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score -3.12 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Accounts ReceivableValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $17.8M | +6.7% |
| FY2024 | $16.6M | +1197.7% |
| FY2023 | $1.3M | +772.8% |
| FY2022 | $147.0K | -99.7% |
| FY2021 | $51.8M | +1072.4% |
| FY2020 | $4.4M | -14.4% |
| FY2019 | $5.2M | +131.4% |
| FY2018 | $2.2M | +100.6% |
| FY2017 | $1.1M | - |
| FY2016 | - | - |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026